Cargando…
IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
Autores principales: | WAQAR, HAFIZA HAREEM, MAHMOOD, FATIMA, NAUTIYAL, AMIT |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548847/ http://dx.doi.org/10.1016/j.chest.2022.08.1547 |
Ejemplares similares
-
ASSESSMENT OF RESPIRATORY FUNCTION IN PATIENTS AFTER SARS-COV-2 LUNG DISEASE
por: PINI, LAURA, et al.
Publicado: (2021) -
DRUG-INDUCED PNEUMONITIS IN THE SETTING OF SARS-COV-2 INFECTION
por: UDEH, UBA C, et al.
Publicado: (2022) -
SEVERE COVID-19 ASSOCIATED WITH ADVANCED FORMS OF PULMONARY TB DISEASE IN AN ENDEMIC AREA OF ROMANIA
por: ARGHIR, I., et al.
Publicado: (2022) -
SEATED-IMMOBILITY THROMBOEMBOLISM SYNDROME COMPLICATING CORONAVIRUS DISEASE 2019 OUTBREAK QUARANTINE
por: Ali, Abdulla, et al.
Publicado: (2020) -
Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy
por: Czekalska, Anna, et al.
Publicado: (2019)